X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Cadila Healthcare with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs MYLAN (US) - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 CADILA HEALTHCARE   MYLAN
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-18
MYLAN
Dec-14
CADILA HEALTHCARE/
MYLAN
5-Yr Chart
Click to enlarge
High Rs5584,249-   
Low Rs3622,995-   
Sales per share (Unadj.) Rs116.31,454.8-  
Earnings per share (Unadj.) Rs17.9175.2-  
Cash flow per share (Unadj.) Rs23.1282.1-  
Dividends per share (Unadj.) Rs3.500-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs85.4723.2-  
Shares outstanding (eoy) m1,023.74378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x4.02.5 158.8%   
Avg P/E ratio x25.720.7 124.5%  
P/CF ratio (eoy) x19.912.8 154.8%  
Price / Book Value ratio x5.45.0 107.5%  
Dividend payout %19.60-   
Avg Mkt Cap Rs m470,6641,370,471 34.3%   
No. of employees `00011.825.0 47.3%   
Total wages/salary Rs m18,5450-   
Avg. sales/employee Rs Th10,072.722,017.4 45.7%   
Avg. wages/employee Rs Th1,569.10-   
Avg. net profit/employee Rs Th1,547.72,652.4 58.4%   
INCOME DATA
Net Sales Rs m119,049550,436 21.6%  
Other income Rs m1,132-3,209 -35.3%   
Total revenues Rs m120,181547,228 22.0%   
Gross profit Rs m28,475136,896 20.8%  
Depreciation Rs m5,38840,427 13.3%   
Interest Rs m91123,743 3.8%   
Profit before tax Rs m23,30869,518 33.5%   
Minority Interest Rs m628-285 -220.2%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,6442,923 193.1%   
Profit after tax Rs m18,29266,309 27.6%  
Gross profit margin %23.924.9 96.2%  
Effective tax rate %24.24.2 575.8%   
Net profit margin %15.412.0 127.5%  
BALANCE SHEET DATA
Current assets Rs m82,005483,906 16.9%   
Current liabilities Rs m60,720378,318 16.0%   
Net working cap to sales %17.919.2 93.2%  
Current ratio x1.41.3 105.6%  
Inventory Days Days7378 93.7%  
Debtors Days Days98107 91.6%  
Net fixed assets Rs m83,703127,342 65.7%   
Share capital Rs m1,02419,465 5.3%   
"Free" reserves Rs m86,4210-   
Net worth Rs m87,445273,621 32.0%   
Long term debt Rs m25,551408,763 6.3%   
Total assets Rs m180,6531,102,120 16.4%  
Interest coverage x26.63.9 676.8%   
Debt to equity ratio x0.31.5 19.6%  
Sales to assets ratio x0.70.5 131.9%   
Return on assets %10.68.2 130.1%  
Return on equity %20.924.2 86.3%  
Return on capital %22.013.6 161.4%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m31,4410-   
CASH FLOW
From Operations Rs m9,19372,355 12.7%  
From Investments Rs m-9,737-57,061 17.1%  
From Financial Activity Rs m515-19,066 -2.7%  
Net Cashflow Rs m-29-3,772 0.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 71.3 Rs / USD

Compare CADILA HEALTHCARE With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare CADILA HEALTHCARE With: DIVIS LABORATORIES  ALKEM LABORATORIES  TTK HEALTHCARE  CIPLA  GSK PHARMA  



Today's Market

Sensex Ends 274 Points Lower; IT and Energy Stocks Witness Selling(Closing)

Share markets in India continued to witness selling pressure during closing hours and ended their trading session on a negative note.

Related Views On News

CADILA HEALTHCARE Announces Quarterly Results (2QFY19); Net Profit Down 18.6% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (down 18.6% YoY). Sales on the other hand came in at Rs 30 bn (down 8.4% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of CADILA HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY19); Net Profit Up 274.4% (Quarterly Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

For the quarter ended June 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (up 274.4% YoY). Sales on the other hand came in at Rs 29 bn (up 29.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Nov 21, 2018 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE - SUN PHARMA COMPARISON

COMPARE CADILA HEALTHCARE WITH

MARKET STATS